A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
about
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A phase 2 safety study of acce ...... atients with multiple myeloma.
@en
type
label
A phase 2 safety study of acce ...... atients with multiple myeloma.
@en
prefLabel
A phase 2 safety study of acce ...... atients with multiple myeloma.
@en
P2093
P2860
P356
P1476
A phase 2 safety study of acce ...... atients with multiple myeloma.
@en
P2093
Alan Cartmell
Ali Nourbakhsh
Hesham Mohamed
Kristi McIntyre
Robert Manges
Robert Rifkin
Roger Lyons
Suprith Badarinath
P2860
P304
P356
10.1002/AJH.24687
P577
2017-02-18T00:00:00Z